Showing results (1441-1450 of 2,038) with videos related to

Sort By:
Pageof 204
Zhonghua Wai Ke Za Zhi [Chinese Journal of Surgery]|December 30, 2020
[Prognosis analysis of local recurrence after excision of breast phyllodes tumors]Y Peng, Y Y Zhang, S C Wang, et al.
JAMA Psychiatry|January 22, 2016
Type 2 Diabetes Mellitus in Youth Exposed to Antipsychotics: A Systematic Review and Meta-analysisBritta Galling, Alexandra Roldán, René E Nielsen, et al.
Experimental Hematology|January 29, 1999
The prolonged hematologic effects of a single injection of PEG-rHuMGDF in normal and thrombocytopenic miceT R Ulich, J del Castillo, G Senaldi, et al.
European Journal of Cancer Care|August 5, 2017
The international phase 4 validation study of the EORTC QLQ-SWB32: A stand-alone measure of spiritual well-being for people receiving palliative care for cancerB Vivat, T E Young, J Winstanley, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2017
Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trialJ Guo, R D Carvajal, R Dummer, et al.
The Journal of Clinical Investigation|May 20, 2021
Multiple-ancestry genome-wide association study identifies 27 loci associated with measures of hemolysis following blood storageGrier P Page, Tamir Kanias, Yuelong J Guo, et al.
Zhonghua Yi Xue Za Zhi|July 9, 2024
[Clinical features and prognostic factors of advanced myelodysplastic syndromes in children]C M Liu, Y L Chen, X C Wang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 16, 2022
Toripalimab (anti-PD-1) versus high-dose interferon-α2b as adjuvant therapy in resected mucosal melanoma: a phase II randomized trialB Lian, L Si, Z H Chi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 11, 2025
Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trialT Powles, S Tagawa, C Vulsteke, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 30, 2025
Randomized, Double-Blind, Phase III LEAP-003 Study of First-Line Lenvatinib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab for Unresectable or Metastatic MelanomaA Arance, M-A Berciano-Guerrero, J Guo, et al.
Pageof 204